<DOC>
	<DOCNO>NCT02907320</DOCNO>
	<brief_summary>Chronic Venous Disorder prevalent vascular disease . It multifactorial pathology important impact quality life represent significant public health concern , due high frequency European American ( north south ) country . Venous pathology develop venous pressure increase return blood impair several mechanism . Wish induce leg symptom ( tingle , ache , burning , pain , muscle cramp , sensation swelling , sensation throb heaviness , itch skin , restless leg , leg tiredness and/or fatigue . The aim research study effect microcirculatory activity ( activity small vessel ) CYCLO 3 ® FORT , MPFF ( Micronised Purified Flavonoid Fraction ) Placebo 8 week treatment Microscan , Duplex , two image non-invasive technology perform obtain measurement microcirculatory parameter standardize reproducible condition participant . In addition , ass , blood sample , inflammatory biomarkers .</brief_summary>
	<brief_title>EXPLORATORY ASSESSMENT OF THE EFFECTS OF CYCLO 3 ® FORT ( Ruscus Extract , Hesperidin Methyl Chalcone , Ascorbic Acid ) OR MICRONISED PURIFIED FLAVONOID FRACTION ON VASCULAR PARAMETERS AND BIOMARKERS IN WOMEN SUFFERING FROM CHRONIC VENOUS DISEASE ( CEAP C2 OR C3 ) , OVER 8 WEEKS</brief_title>
	<detailed_description />
	<mesh_term>Ascorbic Acid</mesh_term>
	<criteria>1 . Inclusion criterion Nonmenopausal woman age 18 50 year Symptomatic Primary chronic disorder C2 C3 advance CEAP Regular menstrual cycle Use efficient method contraception Having sign write informed 2 . Noninclusion criterion 2.1 Related pathology : Superficial deep venous thrombosis Venous insufficiency include history deep venous thrombosis , post thrombotic syndrome , venous dysplasia , compressive syndrome History venous strap phlebotomy/ surgery evaluate leg Sclerosing injection within 6 month inclusion Oedema etiology Paresthesia , cramp low limb origin 2.2 Related treatment : Hypersensitivity , allergy intolerance study drug Iron storage disorder Intake venotonic treatment ( oral topic ) , triptan , diuretic , calcium blocker , beta blocker , ACE inhibitor , angiotensine II inhibitor , vasodilatators and/or vasoconstrictor within 1 month inclusion Intake NSAID , corticosteroid , ergotamine , dihydroergotamine ergot alkaloid , vitamin C nutraceutical phytotherapy product potential venotonic effect within 2 week inclusion 2.3 Related population : History diabetes BMI≥ 30 Grade V VI Fitzpatrick classification</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>